How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

34,777 results for

Hypertension Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Atlantoaxial Misalignment Causes High Blood Pressure in Rats: A Novel Hypertension Model (PubMed)

Atlantoaxial Misalignment Causes High Blood Pressure in Rats: A Novel Hypertension Model Atlantoaxial disorders are often correlated with hypertension in practice. In order to study the relationship between atlantoaxial disorder and hypertension, we attempted to construct an animal model. In this work, we presented an animal model where their atlantoaxial joints were misaligned. We investigated the changes of blood pressure before and after treatments of the modeled rats. We had the following (...) , we concluded that we successfully constructed cervical atlantoaxial disorder models in rats that showed hypertension symptom. However, the underlying mechanism connecting atlantoaxial disorder and hypertension still requires further study.

Full Text available with Trip Pro

2017 BioMed research international

102. Severe pulmonary hypertension due to combined pulmonary fibrosis and emphysema: another cause of death among smokers (PubMed)

Severe pulmonary hypertension due to combined pulmonary fibrosis and emphysema: another cause of death among smokers In 2005, the combined pulmonary fibrosis and emphysema (CPFE) was first defined as a distinct entity, which comprised centrilobular or paraseptal emphysema in the upper pulmonary lobes, and fibrosis in the lower lobes accompanied by reduced diffused capacity of the lungs for carbon monoxide (DLCO). Recently, the fibrosis associated with the connective tissue disease was also (...) included in the diagnosis of CPFE, although the exposure to tobacco, coal, welding, agrochemical compounds, and tire manufacturing are the most frequent causative agents. This entity characteristically presents reduced DLCO with preserved lung volumes and severe pulmonary hypertension, which is not observed in emphysema and fibrosis alone. We present the case of a 63-year-old woman with a history of heavy tobacco smoking abuse, who developed progressive dyspnea, severe pulmonary hypertension, and cor

Full Text available with Trip Pro

2017 Autopsy & Case Reports

103. Linking Vascular Remodeling and Inflammation in Pulmonary Arterial Hypertension: Is There a Common Root Cause? (PubMed)

Linking Vascular Remodeling and Inflammation in Pulmonary Arterial Hypertension: Is There a Common Root Cause? 28665225 2018 02 21 2018 11 13 1535-4989 57 1 2017 07 American journal of respiratory cell and molecular biology Am. J. Respir. Cell Mol. Biol. Linking Vascular Remodeling and Inflammation in Pulmonary Arterial Hypertension: Is There a Common Root Cause? 15-17 10.1165/rcmb.2017-0102ED Thistlethwaite Patricia A PA 1 Division of Cardiothoracic Surgery University of California, San Diego (...) La Jolla, California. eng Editorial United States Am J Respir Cell Mol Biol 8917225 1044-1549 0 Transcription Factors IM Animals Gene Expression Regulation Humans Hypertension, Pulmonary genetics metabolism pathology Inflammation genetics metabolism pathology Transcription Factors genetics metabolism Vascular Remodeling genetics 2017 7 1 6 0 2017 7 1 6 0 2018 2 22 6 0 ppublish 28665225 10.1165/rcmb.2017-0102ED PMC5516285 Oncogene. 2015 Apr 16;34(16):2022-31 24909161 Semin Cell Dev Biol. 2011 Dec

Full Text available with Trip Pro

2017 American journal of respiratory cell and molecular biology

104. Hypertension in Obese Black Women is Not Caused by Increased Sympathetic Vascular Tone (PubMed)

Hypertension in Obese Black Women is Not Caused by Increased Sympathetic Vascular Tone Black women have one of the highest prevalence rates of hypertension and obesity in the United States. We previously reported that sympathetic activation induced by obesity is a significant contributor to hypertension in white patients. It is unknown whether sympathetic activity similarly contributes to hypertension in obese black women.We studied 42 obese women (16 white, body mass index 36±4 kg/m2, 44 (...) % with hypertension; 26 black, body mass index 35±4 kg/m2, 46% with hypertension). Antihypertensive medications were discontinued for 2 weeks before the day of the study. All patients underwent complete autonomic blockade with trimethaphan at a dosage of 4 mg/min. Resting sympathetic activity determined from muscle sympathetic nerve recordings was similar between obese black women with hypertension and those with normotension. In whites, sympathetic activity was elevated in obese patients with hypertension

Full Text available with Trip Pro

2017 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

105. Phosphodiesterase 5 inhibitors for pulmonary hypertension. (PubMed)

'Summary of findings' tables.We included 36 studies with 2999 participants (with pulmonary hypertension from all causes) in the final review. Trials were conducted for 14 weeks on average, with some as long as 12 months. Two trials specifically included children.Nineteen trials included group 1 PAH participants. PAH participants treated with PDE5 inhibitors were more likely to improve their WHO functional class (odds ratio (OR) 8.59, 95% confidence interval (CI) 3.95 to 18.72; 4 trials, 282 (...) Phosphodiesterase 5 inhibitors for pulmonary hypertension. Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right-heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left-heart disease (PH-LHD); Group 3 comprises PH as a result of lung diseases or hypoxia, or both; Group 4

2019 Cochrane

106. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. (PubMed)

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. This is the first update of a Cochrane Review first published in 2015. Renin angiotensin system (RAS) inhibitors include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and renin inhibitors. They are widely prescribed for treatment of hypertension, especially for people with diabetes because of postulated advantages for reducing (...) diabetic nephropathy and cardiovascular morbidity and mortality. Despite widespread use for hypertension, the efficacy and safety of RAS inhibitors compared to other antihypertensive drug classes remains unclear.To evaluate the benefits and harms of first-line RAS inhibitors compared to other first-line antihypertensive drugs in people with hypertension.The Cochrane Hypertension Group Information Specialist searched the following databases for randomized controlled trials up to November 2017

2018 Cochrane

107. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. (PubMed)

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. This is the first update of the review published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also increase (...) adverse events. The optimal blood pressure target in people with hypertension and established cardiovascular disease remains unknown.To determine if 'lower' blood pressure targets (≤ 135/85 mmHg) are associated with reduction in mortality and morbidity as compared with 'standard' blood pressure targets (≤ 140 to 160/90 to 100 mmHg) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive disease

2018 Cochrane

108. Idiopathic intracranial hypertension

and the related neuroimaging signs. Furthermore, no secondary cause of intracranial hypertension is apparent. IIH can either be self-limited or have a lifelong chronic course. Wall M. Idiopathic intracranial hypertension. Neurol Clin. 2010;28:593-617. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908600/ http://www.ncbi.nlm.nih.gov/pubmed/20637991?tool=bestpractice.com Shah VA, Kardon RH, Lee AG, et al. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. Neurology. 2008;70:634-640 (...) Idiopathic intracranial hypertension Idiopathic intracranial hypertension - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Idiopathic intracranial hypertension Last reviewed: February 2019 Last updated: October 2018 Summary The most popular hypothesis is that idiopathic intracranial hypertension (IIH) is a syndrome of reduced cerebrospinal fluid absorption. Clinical features include headaches, pulse-synchronous

2018 BMJ Best Practice

109. Idiopathic pulmonary arterial hypertension

and include dyspnoea on exertion, fatigue, and a loud pulmonary component of the second heart sound. Diagnosis of exclusion. Transthoracic Doppler echocardiography and right heart catheterisation can diagnose pulmonary hypertension. Laboratory tests and imaging studies can rule out known causes of pulmonary hypertension. General supportive therapy includes oral anticoagulants, diuretics, supplemental oxygen, and digoxin. Targeted treatment options include parenteral and inhaled prostanoids, oral (...) (PVR) and, ultimately, right ventricular failure and death. Humbert M, Sitbon O, Simmonnau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436. http://www.ncbi.nlm.nih.gov/pubmed/15459304?tool=bestpractice.com It is defined by a mean pulmonary arterial pressure >25 mmHg at rest with pulmonary capillary wedge pressure <15 mmHg and PVR >3 Woods units, without a known cause. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial

2018 BMJ Best Practice

110. Essential hypertension

for all patients: weight loss, exercise, decreased sodium intake, Dietary Approaches to Stop Hypertension (DASH) diet, and moderation of alcohol consumption. Choice of drug therapy is often driven by considerations related to comorbid disease, but achievement of blood pressure goal may be accomplished with a variety of therapeutic agent(s). Definition Essential hypertension is defined as blood pressure (BP) ≥140/90 mmHg, with no secondary cause identified. National Heart, Lung, and Blood Institute (...) Essential hypertension Essential hypertension - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Essential hypertension Last reviewed: February 2019 Last updated: March 2019 Summary Typically diagnosed by screening of an asymptomatic individual. Treatment of uncontrolled hypertension reduces the risks of mortality and of cardiac, vascular, renal, and cerebrovascular complications. Lifestyle changes are recommended

2018 BMJ Best Practice

111. Idiopathic intracranial hypertension

and the related neuroimaging signs. Furthermore, no secondary cause of intracranial hypertension is apparent. IIH can either be self-limited or have a lifelong chronic course. Wall M. Idiopathic intracranial hypertension. Neurol Clin. 2010;28:593-617. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908600/ http://www.ncbi.nlm.nih.gov/pubmed/20637991?tool=bestpractice.com Shah VA, Kardon RH, Lee AG, et al. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. Neurology. 2008;70:634-640 (...) Idiopathic intracranial hypertension Idiopathic intracranial hypertension - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Idiopathic intracranial hypertension Last reviewed: February 2019 Last updated: October 2018 Summary The most popular hypothesis is that idiopathic intracranial hypertension (IIH) is a syndrome of reduced cerebrospinal fluid absorption. Clinical features include headaches, pulse-synchronous

2018 BMJ Best Practice

112. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. (PubMed)

Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Pre-eclampsia and eclampsia are common causes of serious morbidity and death. Calcium supplementation may reduce the risk of pre-eclampsia, and may help to prevent preterm birth. This is an update of a review last published in 2014.To assess the effects of calcium supplementation during pregnancy on hypertensive disorders of pregnancy and related maternal and child outcomes.We searched Cochrane (...) numbers.The limited evidence on low-dose calcium supplementation suggests a reduction in pre-eclampsia, hypertension and admission to neonatal high care, but needs to be confirmed by larger, high-quality trials.

2018 Cochrane

113. Do Soft Drinks Cause Hypertension?

Do Soft Drinks Cause Hypertension? Do Soft Drinks Cause Hypertension? – Clinical Correlations Search Do Soft Drinks Cause Hypertension? July 8, 2011 6 min read By Ivan Saraiva, MD Faculty Peer Reviewed Sugared soft drinks are among the most heavily consumed drinks in the US. Carbonated soft drinks were first invented as a way to make “healthier” water that looked like natural carbonated waters that were found in European spas in the mountains. The name soda came from the use of bicarbonate (...) with treatment of hyperuricemia with allopurinol ( .(3). An observational study of soft drinks intake in adolescents found increased uric acid levels [4]. Although uric acid may cause hypertension and mediate some of the pathologic consequences classically associated with longstanding high blood pressure in mice, humans are more complex. Studies have been conflicting. Antagonizing or decreasing uric acid with vitamin C was not associated with a decreased risk of hypertension in the Nurses’ Health [5-8

2011 Clinical Correlations

114. Do oral decongestants have a clinically significant effect on BP in patients with hypertension?

with hypertension? View/ Open Date 2017 Format Metadata Abstract Do oral decongestants have a clinically significant effect on BP in patients with hypertension? Evidence-based answer: It is unclear. Pseudoephedrine causes an average increase of 1.2 mm Hg in systolic blood pressure (BP) in patients with controlled hypertension. However, the studies are not adequately powered to provide evidence about whether this rise in systolic BP is linked to patient-oriented outcomes (strength of recommendation [SOR]: C (...) Do oral decongestants have a clinically significant effect on BP in patients with hypertension? Do oral decongestants have a clinically significant effect on BP in patients with hypertension? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do oral decongestants have a clinically significant effect on BP in patients

2018 Clinical Inquiries

115. Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension

with CKD or hypertension at risk of kidney damage who require proteinuria testing People with diabetes at risk of CKD, pregnancy, children (<18 years), people with secondary hypertension Intervention Urine ACR Comparison/ comparators Urine PCR Outcomes CKD progression, measured by: change in eGFR occurrence of end stage kidney disease acute kidney injury initiation of renal replacement therapy All-cause mortality Cardiovascular mortality Diagnostic accuracy outcomes Study design Randomised or non (...) Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension Page 1 of 6 TER005 December 2018 Topic Exploration Report Topic explorations are designed to provide a high-level briefing on new topics submitted for consideration by Health Technology Wales. The main objectives of this report are to: 1. Inform discussions on new topics received by HTW. 2. Determine the quantity and type of evidence available

2019 Health Technology Wales

116. Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period

or a hypertensive exacerba- tion with acutely worsening, difficult to control, severe hypertension. Acute-onset, severe hypertension that is accu- rately measured using standard techniques and is persistent for 15 minutes or more is considered a hypertensive emergency. It is well known that severe hypertension can cause central nervous system injury. As stated in the Confidential Enquiries report from the United Kingdom, two thirds of the maternal deaths during 2003–2005 resulted from cerebral hemorrhage (...) in recommended dosage intervals between these options, which reflect differences in their pharmacokinetics. Although all three medications are appropriately used for the treatment of hypertensive emergencies in pregnancy, each agent can be associated with adverse effects. Parenteral hydralazine may increase the risk of maternal hypotension (systolic BP, 90 mm Hg or less) (22). Parenteral labetalol may cause neonatal bradycardia and should be avoided in women with asthma, heart disease, or congestive heart

2019 American College of Obstetricians and Gynecologists

117. Hypertension

targets for the treatment of people with hypertension and cardiovascular disease. BACKGROUND: This is the first update of the review published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also (...) increase adverse (...) Hypertension Top results for hypertension - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Latest and Greatest

118. ESC/ESH Management of Arterial Hypertension

hypertension3069 8.1.4 Treatment of resistant hypertension3070 8.2 Secondary hypertension3071 8.2.1 Drugs and other substances that may cause secondary hypertension3071 8.2.2 Genetic causes of secondary hypertension3071 8.3 Hypertension urgencies and emergencies3074 8.3.1 Acute management of hypertensive emergencies3075 8.3.2 Prognosis and follow-up3075 8.4 White-coat hypertension3076 8.5 Masked hypertension3077 8.6 Masked uncontrolled hypertension3077 8.7 Hypertension in younger adults (age <50 years)3077 (...) , hypertension remains the major preventable cause of cardiovascular disease (CVD) and all-cause death globally and in our continent. These 2018 ESC/ESH Guidelines for the management of arterial hypertension are designed for adults with hypertension, i.e. aged ≥18 years. The purpose of the review and update of these Guidelines was to evaluate and incorporate new evidence into the Guideline recommendations. The specific aims of these Guidelines were to produce pragmatic recommendations to improve

Full Text available with Trip Pro

2018 European Society of Cardiology

119. Systemic mastocytosis: A rare cause of non-cirrhotic portal hypertension (PubMed)

Systemic mastocytosis: A rare cause of non-cirrhotic portal hypertension Mastocytosis is a clonal neoplastic disorder of the mast cells (MC) that can be limited to the skin (cutaneous mastocytosis) or involve one or more extracutaneous organs (systemic mastocytosis). The clinical manifestations of mastocytosis are heterogeneous ranging from indolent disease with a long-term survival to a highly aggressive neoplasm with survival of about 6 mo. Although liver involvement in aggressive systemic (...) mastocytosis (ASM) is relatively common, the development of portal hypertension with or without cirrhosis is rare. We report a case of ASM without skin involvement in a 72-year-old caucasian male who presented with non-cirrhotic portal hypertension based on clinical, analytical, imagiological and endoscopic findings. Given the hematological picture, the correct diagnosis was established based on ancillary tests for MC using bone marrow aspirates and biopsy. Extensive involvement of the liver

Full Text available with Trip Pro

2016 World Journal of Gastroenterology

120. Very Early Presentation of Extrahepatic Portal Vein Obstruction Causing Portal Hypertension in an Infant: Uncertainties in the Management and Therapeutic Limitations (PubMed)

Very Early Presentation of Extrahepatic Portal Vein Obstruction Causing Portal Hypertension in an Infant: Uncertainties in the Management and Therapeutic Limitations Extrahepatic portal vein obstruction, although rare in children, is a significant cause of portal hypertension (PHT) leading to life-threatening gastrointestinal bleeding in the pediatric age group. PHT may also lead to other complications such as hyperesplenism, cholangyopathy, ascites, and even hepatopulmonary syndrome (...) and portopulmonary hypertension that may require organ transplantation. Herein we report the case of an asymptomatic 11-month-old infant wherein a hepatomegaly and cavernous transformation of the portal vein was detected by liver ultrasound. Neither signs of thrombosis in arteriovenous system, nor affectation of biliary tract were identified in the magnetic resonance imaging study. A significant enlargement of the caudate lobe of the liver was reported. No risk factors were detected. The differential diagnosis

Full Text available with Trip Pro

2016 Case reports in gastroenterology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>